CAMBRIDGE, MA, Curie Therapeutics, a biotechnology company, announced a Series A investment of $75 million.
Curie Therapeutics, a biotechnology company incubated by Atlas Ventures, Access Biotechnology and RA Capital Management, announced a Series A investment of $75 million by its founding syndicate.
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
